IRX-101
/ Irenix Medical
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
January 13, 2025
COMFORT: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
(clinicaltrials.gov)
- P3 | N=240 | Not yet recruiting | Sponsor: iRenix Medical, Inc. | Trial completion date: Aug 2024 ➔ Dec 2027 | Trial primary completion date: Jun 2024 ➔ Dec 2026
Trial completion date • Trial primary completion date • Ophthalmology • Pain • Retinal Disorders
June 13, 2023
SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)
(clinicaltrials.gov)
- P2 | N=75 | Recruiting | Sponsor: iRenix Medical, Inc. | Phase classification: P3 ➔ P2 | N=240 ➔ 75
Enrollment change • Phase classification • Ophthalmology • Pain • Retinal Disorders
March 03, 2023
SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)
(clinicaltrials.gov)
- P3 | N=240 | Recruiting | Sponsor: iRenix Medical, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Ophthalmology • Pain • Retinal Disorders
March 03, 2023
COMFORT: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
(clinicaltrials.gov)
- P3 | N=240 | Recruiting | Sponsor: iRenix Medical, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Ophthalmology • Pain • Retinal Disorders
March 01, 2023
COMFORT: Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections
(clinicaltrials.gov)
- P3 | N=240 | Not yet recruiting | Sponsor: iRenix Medical, Inc.
New P3 trial • Ophthalmology • Pain • Retinal Disorders
February 28, 2023
SteRilizing Eye SoLution to ImprovE Patient ComFort (RELIEF)
(clinicaltrials.gov)
- P3 | N=500 | Not yet recruiting | Sponsor: iRenix Medical, Inc.
New P3 trial • Ophthalmology • Pain • Retinal Disorders
1 to 6
Of
6
Go to page
1